Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia [1]

Leukemia

Volumn 19, Issue 2, 2005, Pages 286-287

  von Bubnoff, N ^a   Sandherr, M ^b   Schlimok, G ^b   Andreesen, R ^c   Peschel, C ^a   Duyster, Justus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b KLINIKUM AUGSBURG   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD15 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CYTARABINE; IMATINIB; MESSENGER RNA; MICROSOMAL AMINOPEPTIDASE; MITOXANTRONE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN FIP1 LIKE1 PROTEIN; PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

BLAST CELL CRISIS; CASE REPORT; CHILL; CHROMOSOME 8; CHROMOSOME ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; CYTOGENETICS; DOSE RESPONSE; DRUG BINDING; DRUG DOSE REDUCTION; DRUG FEVER; DRUG MEGADOSE; FATALITY; FIBROSIS; FLOW CYTOMETRY; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPERPLASIA; KARYOTYPING; LETTER; LEUKOCYTE COUNT; MALE; MICROSCOPY; MYELOPROLIFERATIVE DISORDER; NEUTROPENIA; NIGHT SWEAT; PLEURA EFFUSION; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; REAL TIME POLYMERASE CHAIN REACTION; SYMPTOMATOLOGY; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 13544267772     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403600     Document Type: Letter

References (7)

1. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002; 359: 1577-1578.
2. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.
3. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102: 3093-3096.
4. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
5. von Bubnoff N, Peschel C, Duyster J. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia 2003; 17: 829-838.
6. Hochhaus A. Cytogenetic and molecular mechanisms of resistance to imatinib. Semin Hematol 2003; 40 (Suppl 3): 69-79.
7. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873-2878.